OSLO, Norway, May 25, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with Betalutin®...
from PR Newswire: //https://ift.tt/2s97m9f
No comments:
Post a Comment